Patents Assigned to Wyeth
  • Patent number: 6770642
    Abstract: The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: August 3, 2004
    Assignee: Wyeth
    Inventors: Derek Cecil Cole, Joseph Raymond Stock, William Joseph Lennox, Ping Zhou
  • Patent number: 6770446
    Abstract: This invention relates to novel modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide-binding activity; wherein the modified host cell comprises: (a) a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, said fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused to either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a luciferase gene operatively associated with the transcriptional activation protein, or a portion thereof; (d) optionally, a deletion or mutation in the chromosomal DNA of the host cell for the transc
    Type: Grant
    Filed: April 24, 2000
    Date of Patent: August 3, 2004
    Assignee: Wyeth
    Inventors: Kathleen H. Young, Jian Cao
  • Publication number: 20040146906
    Abstract: This invention relates to a novel PTH gene. The invention further relates to methods of screening, diagnosis and development of therapies for bone related disorders.
    Type: Application
    Filed: November 10, 2003
    Publication date: July 29, 2004
    Applicant: Wyeth
    Inventors: John Allen Robinson, Vedrana Stojanovic-Susulic, Philip Babij, Richard John Murrills
  • Publication number: 20040147755
    Abstract: This invention provides compounds of Formula I having the structure 1
    Type: Application
    Filed: January 8, 2004
    Publication date: July 29, 2004
    Applicant: Wyeth
    Inventor: Michael S. Malamas
  • Publication number: 20040147007
    Abstract: The present invention describes the identification of novel non-ribosomal peptide synthetases and associated biosynthetic genes from Streptomyces hygroscopicus. The present invention further provides methods for generating novel compounds, such as antibiotics, from these synthetases and associated genes.
    Type: Application
    Filed: December 23, 2003
    Publication date: July 29, 2004
    Applicant: Wyeth
    Inventors: John A. Hucul, Nathan Magarvey, Michael Greenstein
  • Publication number: 20040147476
    Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell.
    Type: Application
    Filed: February 13, 2004
    Publication date: July 29, 2004
    Applicant: Wyeth
    Inventors: Chandrasekhar Satishchandran, Catherine J. Pachuk
  • Publication number: 20040147601
    Abstract: This invention provides O-&agr;-acyloxyalkyl ethers of the venlafaxine metabolite 4-[2-(Dimethylamino-1-(1-hydroxycyclohexyl)ethyl]phenol, represented by Formula (I): 1
    Type: Application
    Filed: October 24, 2003
    Publication date: July 29, 2004
    Applicant: Wyeth
    Inventors: John P. Yardley, Magid A. Abou-Gharbia, John W. Ullrich
  • Patent number: 6767912
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Grant
    Filed: December 20, 2001
    Date of Patent: July 27, 2004
    Assignee: Wyeth
    Inventors: Ping Zhou, Derek Cecil Cole, Michael Gerard Kelly, William Joseph Lennox
  • Publication number: 20040142863
    Abstract: The present invention relates to modified ADAMTS4 proteins having improved stability comparing to the corresponding native, unmodified proteins. The modified ADAMTS4 proteins can be expressed and isolated in large quantities, thus allowing further characterization of the proteins, such as crystallographic and enzyme kinetic studies. The purified, stable proteins would also facilitate the production of anti-ADAMTS antibodies and the development of inhibitors to ADAMTS enzymes.
    Type: Application
    Filed: July 29, 2003
    Publication date: July 22, 2004
    Applicant: WYETH
    Inventors: Christopher John Corcoran, Carl R. Flannery, Weilan Zeng, Lisa A. Racie, Thomas McDonagh, Bethany A. Freeman, Katy E. Georgiadis, Edward R. LaVallie
  • Publication number: 20040142359
    Abstract: The present invention relates generally to the fields of neuroscience, growth factors and depression. More particularly, the present invention addresses the need in the art for methods and compositions for treating neurological disorders such as depression, anxiety, panic disorder, bi-polar disorder, insomnia, obsessive compulsive disorder, dysthymic disorder and schizophrenia. In certain embodiments, the invention relates to non-covalent binding interactions between insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs).
    Type: Application
    Filed: November 12, 2003
    Publication date: July 22, 2004
    Applicant: Wyeth
    Inventors: Christopher William Aston, Jessica Eden Malberg, Xavier Zafar Khawaja
  • Patent number: 6765021
    Abstract: This invention provides compounds of formula I having the structure wherein: B, D, C, and R1 as defined herein.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: July 20, 2004
    Assignee: Wyeth
    Inventors: John A. Butera, Craig E. Caufield, Russell F. Graceffa, Alexander Greenfield, Eric G. Gundersen, Lisa Marie Havran, Alan H. Katz, Joseph R. Lennox, Scott C. Mayer, Robert E. McDevitt
  • Publication number: 20040138302
    Abstract: This disclosure describes antifungal antibiotics designated Hygroscopene A, Hygroscopene B and Hygroscopene C to their production by fermentation, to methods for recovery and concentration from the crude solutions, to a process for purification and to new analogs of Hygroscopene A, Hygroscopene B and Hygroscopene C prepared by synthetic procedures.
    Type: Application
    Filed: December 18, 2003
    Publication date: July 15, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Ping Cai, Fangming Kong, Pamela Fink Charbonneau, Mark Edward Ruppen
  • Publication number: 20040138168
    Abstract: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous to a target polynucleotide sequence. This RNA molecule desirably does not produce a functional protein. The agents useful in the composition can be RNA molecules made by enzymatic synthetic methods or chemical synthetic methods in vitro; or made in recombinant cultures of microorganisms and isolated therefrom, or alternatively, can be capable of generating the desired RNA molecule in vivo after delivery to the mammalian cell. In methods of treatment of prophylaxis of virus infections, other pathogenic infections or certain cancers.
    Type: Application
    Filed: February 6, 2004
    Publication date: July 15, 2004
    Applicant: Wyeth
    Inventors: Chandrasekhar Satishchandran, Catherine J. Pachuk
  • Publication number: 20040138251
    Abstract: This invention provides compounds of Formula (Ia)-(If) 1
    Type: Application
    Filed: November 21, 2003
    Publication date: July 15, 2004
    Applicant: Wyeth
    Inventors: Diane Harris Boschelli, Nan Zhang, Ana Carolina Barrios Sosa, Haris Durutlic, Biqi Wu
  • Publication number: 20040138283
    Abstract: Compounds of formula I are provided: 1
    Type: Application
    Filed: December 9, 2003
    Publication date: July 15, 2004
    Applicant: Wyeth
    Inventors: Lee Dalton Jennings, Hassan Mahmoud Elokdah, Geraldine Ruth McFarlane
  • Patent number: 6762327
    Abstract: A safe and effective process for the oxidation of a primary or secondary alcohol to the corresponding aldehyde or ketone via the reaction of said alcohol with an anhydride solution of a 1,1,1-tri(C2-C4 alkanoyloxy-1,1-dihydro-1,2-benziodoxol-3(1H)-one, and a composition useful in this process.
    Type: Grant
    Filed: April 3, 2003
    Date of Patent: July 13, 2004
    Assignee: Wyeth
    Inventors: Ugo Chiacchio, Antonio Rescifina, Giuseppe Miraglia, Mariangela Magnano, Paola Di Raimondo
  • Patent number: 6762178
    Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.
    Type: Grant
    Filed: June 14, 2001
    Date of Patent: July 13, 2004
    Assignee: Wyeth Holdings Corporation
    Inventors: Jeremy I. Levin, James M. Chen
  • Publication number: 20040132812
    Abstract: The invention relates to new antibiotics designated Cyan-416A, Cyan 416B, Cyan-416C, Cyan-416D and Cyan-416E to their production by fermentation of Acremonium sp. NRRL 30631 to methods for recovery and concentration from the crude solutions, and to a process for purification and to semisynthetic ethers of Cyan-416B.
    Type: Application
    Filed: December 15, 2003
    Publication date: July 8, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Haiyin He, Ramunas Bigelis
  • Publication number: 20040132741
    Abstract: The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 8, 2004
    Applicant: Wyeth
    Inventors: Michael Gerard Kelly, Derek Cecil Cole
  • Publication number: 20040131640
    Abstract: A vaccine against Newcastle Disease contains one or more mutant immunogens of the NDW strain. The mutant immunogen lacks the antigenic binding site on the F glycoprotein which is recognized by the monoclonal antibody mAb 54. Reagent kits and assay methods help to distinguish vaccinated members of a poultry flock from those that may have been infected with wild-type Newcastle Disease virus.
    Type: Application
    Filed: December 2, 2003
    Publication date: July 8, 2004
    Applicant: Wyeth
    Inventors: Harmen J. Geerligs, Ian Hamer Brown, Dennis John Alexander, Michael Sinclair Collins